Health & Environmental Research Online (HERO)


Print Feedback Export to File
3859800 
Journal Article 
Per- and polyfluoroalkyl substances in human serum and urine samples from a residentially exposed community 
Worley, RR; Moore, SM; Tierney, BC; Ye, X; Calafat, AM; Campbell, S; Woudneh, MB; Fisher, J 
2017 
Environment International
ISSN: 0160-4120
EISSN: 1873-6750 
Elsevier 
OXFORD 
106 
Elsevier 
135-143 
English 
BACKGROUND: Per- and polyfluoroalkyl substances (PFAS) are considered chemicals of emerging concern, in part due to their environmental and biological persistence and the potential for widespread human exposure. In 2007, a PFAS manufacturer near Decatur, Alabama notified the United States Environmental Protection Agency (EPA) it had discharged PFAS into a wastewater treatment plant, resulting in environmental contamination and potential exposures to the local community.

OBJECTIVES: To characterize PFAS exposure over time, the Agency for Toxic Substances and Disease Registry (ATSDR) collected blood and urine samples from local residents.

METHODS: Eight PFAS were measured in serum in 2010 (n=153). Eleven PFAS were measured in serum, and five PFAS were measured in urine (n=45) from some of the same residents in 2016. Serum concentrations were compared to nationally representative data and change in serum concentration over time was evaluated. Biological half-lives were estimated for perfluorooctanoic acid (PFOA), perfluorooctane sulfonic acid (PFOS), and perfluorohexane sulfonic acid (PFHxS) using a one-compartment pharmacokinetic model.

RESULTS: In 2010 and 2016, geometric mean PFOA and PFOS serum concentrations were elevated in participants compared to the general U.S.

POPULATION: In 2016, the geometric mean PFHxS serum concentration was elevated compared to the general U.S.

POPULATION: Geometric mean serum concentrations of PFOA, PFOS, and perfluorononanoic acid (PFNA) were significantly (p≤0.0001) lower (49%, 53%, and 58%, respectively) in 2016 compared to 2010. Half-lives for PFOA, PFOS, and PFHxS were estimated to be 3.9, 3.3, and 15.5years, respectively. Concentrations of PFOA in serum and urine were highly correlated (r=0.75) in males.

CONCLUSIONS: Serum concentrations of some PFAS are decreasing in this residentially exposed community, but remain elevated compared to the U.S. general population. 
Biomonitoring; Half-life 
PFAS
• Additional PFAS (formerly XAgency)
• Expanded PFAS SEM (formerly PFAS 430)
     Litsearch: September 2019
          PubMed
          Web of Science
     Screened Studies
          Supplemental
     Perfluorooctane
• ^Per- and Polyfluoroalkyl Substances (PFAS)
     PFOA (335-67-1) and PFOS (1763-23-1)
          Literature Search – Adverse outcome pathway (2015-present)
               Pubmed
               WOS
     PFNA (375-95-1)
          Literature Search
               Pubmed
     PFHxS (355-46-4)
          Literature search
               Pubmed
• PFAS 150
     Literature Search Update December 2020
          PubMed
          WOS
     Literature Search August 2019
          PubMed
          Web of Science
     Not prioritized for screening
     Ammonium perfluorooctanoate
     Perfluorohexanesulfonic acid
     Perfluorononanoic acid
     Perfluorooctane
     Perfluorooctanesulfonate
     Perfluorooctanesulfonic acid
     Perfluorooctanoic acid
• PFBA
     Protocol References
• PFDA
     Scopus: April 2021
• PFHxS
     Database searches
          Pubmed
          Toxline
          WOS
          Scopus
     Inclusion
          TiAb
     Supplemental
          Full Text
• PFNA
     Literature Search (August 2017)
          Pubmed
     Litsearch Update 2017-2018
          PFAS Untag
     PFNA Literature Search pre-2019
          WOS
     Literature Search
          Pubmed
          Toxline
          WOS
     PFNA May 2019 Update
          Pubmed
          Toxnet
          Web of Science
     Screening Results
          Excluded/Not on Topic
     Title and Abstract Screening
          Excluded
               Not relevant to PECO
• PFOA (335-67-1) and PFOS (1763-23-1)
     Literature Search – Adverse outcome pathway (2015-present)
          Pubmed
          WOS
     Screening Results
          Excluded/Not on Topic
     Literature Search Update (2013-2019)
          PubMed
          WOS
• PFOA and PFOS OW MCLG Approaches
     Cited in White Papers